Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1CNS 1

Conditions

Glioblastoma 52Brain Neoplasms 28Glioma 22Gliosarcoma 19Melanoma 18Astrocytoma 17Central Nervous System Neoplasms 11Oligodendroglioma 10Neoplasms 9Neoplasm Metastasis 8Recurrence 6Carcinoma, Non-Small-Cell Lung 5Neuroblastoma 4Lymphoma 4Ependymoma 4Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Sarcoma, Ewing 2Neurologic Manifestations 2Neuroectodermal Tumors, Primitive 2Neoplasms, Second Primary 2Meningeal Carcinomatosis 2Medulloblastoma 2Bone Neoplasms 2Urinary Bladder Neoplasms 1Thrombocytopenia 1Tetanus 1Spinal Cord Neoplasms 1Solid Tumors 1Small Cell Lung Cancer Recurrent 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × Temozolomide × Clear all
NCT04851834 2022-12-20

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Xennials Therapeutics Australia Pty Ltd

Phase 1/2 Terminated
12 enrolled
CNSGenitourinaryGynecologic

Urinary Bladder Neoplasms, Glioma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡